01:44 , Aug 16, 2019 |  BC Innovations  |  Targets & Mechanisms

Biotechs explore the next generation of inflammasome targets, with caution

As the NLRP3 field gains momentum, drawing VC and pharma interest for the role the target plays in diseases ranging from NASH to neurodegeneration, biotechs are beginning to eye the next crop of inflammasome targets....
18:17 , Aug 12, 2019 |  BC Extra  |  Company News

Vertex fails to reach CF deal in Scotland

Two of Vertex's cystic fibrosis drugs continue to remain unavailable in the U.K. after the Scottish Medicines Consortium rejected their coverage on NHS, citing a lack of long-term data to support the price. "As these...
12:40 , Aug 12, 2019 |  BioCentury  |  Finance

Chipscreen sets high standard in Shanghai debut

Chipscreen became the first biopharma to begin trading on Shanghai’s STAR market this week, and the strength of its debut could entice companies sitting on the sidelines to choose a mainland listing over one in...
00:00 , Aug 1, 2019 |  BC Extra  |  Company News

Vertex’s CF ‘firepower’ to fund more deals, broader pipeline

Vertex unveiled a series of new programs Wednesday and provided a glimpse of how it plans to use the cash from its cystic fibrosis portfolio to fuel deals that will continue to propel the company...
00:19 , Jul 31, 2019 |  BC Extra  |  Clinical News

July 30 Clinical Quick Takes: Biogen, Alkermes MS candidate superior to Tecfidera; plus Amgen, Lilly and more

Biogen, Alkermes Phase III MS candidate beats Tecfidera  Biogen Inc. (NASDAQ:BIIB) and Alkermes plc (NASDAQ:ALKS) said diroximel fumarate (BIIB098) met the primary endpoint in the Phase III EVOLVE-MS-2 trial: superiority to Biogen’s Tecfidera dimethyl fumarate...
21:07 , Jul 26, 2019 |  BioCentury  |  Finance

Earnings on deck

Earnings on deck At least 27 profitable biotechs and pharmas are slated to report earnings this week. (A) During market hours in Europe, premarket on U.S. exchanges; (B) Fiscal 1Q Company Date Pre/post mkt 2Q19...
23:02 , Jul 25, 2019 |  BC Extra  |  Clinical News

July 25 Clinical Quick Takes: J&J’s ponesimod hits MS endpoint; plus a CRISPR first, Genkyotex and Aeglea

Janssen’s ponesimod tops Aubagio in Phase III  The Janssen Pharmaceuticals unit of Johnson & Johnson (NYSE:JNJ) said it plans to submit NDAs to FDA and EMA this year after reporting ponesimod met the primary endpoint...
20:51 , Jul 25, 2019 |  BC Extra  |  Company News

As Vertex broadens remit, Leiden handing baton to Kewalramani

As Vertex continues to push its pipeline beyond cystic fibrosis, it will do so with a new president and CEO at the helm. Chairman, President and CEO Jeffrey Leiden will step down from his position...
08:06 , Jul 25, 2019 |  BC Extra  |  Company News

Breath takeout gives Zambon lung transplant candidate, U.S. foothold

Italian pharma Zambon is acquiring Sofinnova Partners portfolio company Breath Therapeutics for €140 million ($156 million) up front to expand its respiratory pipeline and establish a foothold in the U.S. Shareholders of Breath Therapeutics B.V....
22:50 , Jul 24, 2019 |  BC Extra  |  Company News

July 24 Management tracks: GSK, Goldman Sachs, Ziopharm and Alkahest

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) announced Wednesday that it has appointed Jonathan Symonds as non-executive chairman to succeed Philip Hampton, effective Sept. 1. Symonds is deputy group chairman at HSBC and has served as CFO Novartis...